Evidence map›Paper›PMID 35518277›Full record

ArticleHardwareX2022

Open source fraction collector/MALDI spotter for proteomics.

Scott B Ficarro, William Max Alexander, Isidoro Tavares, Jarrod A Marto

Open access · goldAbstract read
In one paragraph

Article in HardwareX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Scott B FicarroDepartment of Cancer Biology, Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 360 Longwood Avenue, LC 2208, Boston, MA 02215-5450, USA.
William Max AlexanderDepartment of Cancer Biology, Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 360 Longwood Avenue, LC 2208, Boston, MA 02215-5450, USA.
Isidoro TavaresDepartment of Cancer Biology, Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 360 Longwood Avenue, LC 2208, Boston, MA 02215-5450, USA.
Jarrod A MartoDepartment of Cancer Biology, Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 360 Longwood Avenue, LC 2208, Boston, MA 02215-5450, USA.
Dana-Farber Cancer Institute · USHarvard University · US

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
PROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0M
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell LymphomaR01CA219850 · NCI · DANA-FARBER CANCER INST · PI DANIAL, NIKA N, MARTO, JARROD A. · 2018 to 2022
$2.8M
Novel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5M
Tools for DUB Drug DiscoveryR21CA247671 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2020 to 2021
$648k
NCI NIH HHS P01 CA203655NCI NIH HHS R01 CA219850NCI NIH HHS R01 CA233800NCI NIH HHS R21 CA247671NIDDK NIH HHS U24 DK116204
6 · The paper itself

Abstract

We describe a complete open-source hardware/software solution for high performance thermostatted peptide fraction collection to support mass spectrometry experiments with complex proteomes. The instrument is easy to assemble using parts readily available through retail channels at a fraction of the cost compared to typical commercial systems. Control software is written in Python allowing for rapid customization. We demonstrate several useful applications, including the automated deposition of LC separated peptides for matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) as well as collection and concatenation of peptide fractions from nanoflow HPLC separations.

Indexed as

Fraction collectionHPLC, high pressure liquid chromatographyLC, liquid chromatographyLC-MALDILC-MS, Liquid Chromatography/Mass spectrometryMALDI-MS, matrix-assisted laser desorption ionization mass spectrometryMS, mass spectrometer/mass spectrometryOEM, Original Equipment ManufacturerOpen sourceProteomicsPython

Identifiers

PMID35518277
PMCPMC9062586
OpenAlexW4224035744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.